The potential for PPAR regulators of airway inflammation as potential therapeutic targets for asthma and lung diseases (Standiford et al., 2005; Banno et al., 2018) has already been explored and their application for TB therapeutics could be further explored. The gene discussed is PPARA; the disease is lung disorder.